kv11 1  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs kv11 1
    Kv11 1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kv11 1/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kv11 1 - by Bioz Stars, 2022-08
    93/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Alomone Labs anti kv11 1
    Dominant-negative (DN)-Rab11B-green fluorescent protein (GFP) and Rab11B short hairpin (sh)RNA increases <t>WT-Kv11.1</t> and Bap31 colocalization. A : representative fluorescent images of cells coexpressing WT-Kv11.1 and Rab11B-GFP or DN-Rab11B-GFP immunostained
    Anti Kv11 1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti kv11 1/product/Alomone Labs
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti kv11 1 - by Bioz Stars, 2022-08
    85/100 stars
      Buy from Supplier

    93
    Alomone Labs kv11 1 primary antibody
    <t>Kv11.1</t> channel expression increases in pulmonary arterial hypertension (PAH) rats. A: Hematoxylin and eosin (H E) staining of lung tissue from Sprague-Dawley rats with PAH shows pulmonary arteries (PAs) wall thickness ( arrows ). After SU5416 injection, rats were kept in hypoxia for 3 weeks and then maintained in normoxia for 5 weeks. B: α-Smooth muscle actin (SMA) antibody staining in the media of small PAs (brown; arrows ). C: Kv11.1 antibody staining in the media of small PAs (brown; arrows ). D: Quantification of Kv11.1 channel expression (in arbitrary units; au) in small PAs of healthy and PAH rat lungs. E: Negative control for C with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated ( red lines ). n = 11 (control); n = 18 (PAH). * P
    Kv11 1 Primary Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kv11 1 primary antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kv11 1 primary antibody - by Bioz Stars, 2022-08
    93/100 stars
      Buy from Supplier

    Image Search Results


    Dominant-negative (DN)-Rab11B-green fluorescent protein (GFP) and Rab11B short hairpin (sh)RNA increases WT-Kv11.1 and Bap31 colocalization. A : representative fluorescent images of cells coexpressing WT-Kv11.1 and Rab11B-GFP or DN-Rab11B-GFP immunostained

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: Dominant-negative (DN)-Rab11B-green fluorescent protein (GFP) and Rab11B short hairpin (sh)RNA increases WT-Kv11.1 and Bap31 colocalization. A : representative fluorescent images of cells coexpressing WT-Kv11.1 and Rab11B-GFP or DN-Rab11B-GFP immunostained

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Dominant Negative Mutation

    Pharmacological correction of Kv11.1 current ( I Kv11.1 ) occurs in cells treated with cycloheximide and after 30 min. A : representative I Kv11.1 traces recorded from cells expressing G601S in control conditions ( n = 8 cells) and after E-4031 treatment without

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: Pharmacological correction of Kv11.1 current ( I Kv11.1 ) occurs in cells treated with cycloheximide and after 30 min. A : representative I Kv11.1 traces recorded from cells expressing G601S in control conditions ( n = 8 cells) and after E-4031 treatment without

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Expressing

    G601S and Bap31 show a similar sensitivity to brefeldin a (bfa) and nocodazole (noc). A – D : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column), anti-Bap31 (green, second column), and anti-ERGIC-53

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: G601S and Bap31 show a similar sensitivity to brefeldin a (bfa) and nocodazole (noc). A – D : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column), anti-Bap31 (green, second column), and anti-ERGIC-53

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Expressing

    G601S selectively colocalizes with Bap31. Shown are representative fluorescent images of cells expressing wild-type (WT)-Kv11.1 or G601S immunostained with anti-Kv11.1 (red, first column) and anti-Derlin-1 ( A ), anti-Bap31 ( B ), anti-Sec31 ( C ), or anti-ERGIC-53

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: G601S selectively colocalizes with Bap31. Shown are representative fluorescent images of cells expressing wild-type (WT)-Kv11.1 or G601S immunostained with anti-Kv11.1 (red, first column) and anti-Derlin-1 ( A ), anti-Bap31 ( B ), anti-Sec31 ( C ), or anti-ERGIC-53

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Expressing

    E-4031 treatment decreases G601S and Bap31 colocalization. A : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column) and anti-Bap31 (green, second column) in control conditions ( n = 30 images) and

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: E-4031 treatment decreases G601S and Bap31 colocalization. A : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column) and anti-Bap31 (green, second column) in control conditions ( n = 30 images) and

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Expressing

    Pharmacological correction increases the terminal glycosylation of G601S in cells treated with cycloheximide. A : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column) and anti-Bap31 (green, second

    Journal: American Journal of Physiology - Cell Physiology

    Article Title: Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum

    doi: 10.1152/ajpcell.00406.2012

    Figure Lengend Snippet: Pharmacological correction increases the terminal glycosylation of G601S in cells treated with cycloheximide. A : representative fluorescent images of cells expressing G601S immunostained with anti-Kv11.1 (red, first column) and anti-Bap31 (green, second

    Article Snippet: Cells not expressing Kv11.1 did not show any immunostaining with anti-Kv11.1 (data not shown) nor any of the secondary antibodies alone (data not shown).

    Techniques: Expressing

    Kv11.1 channel expression increases in pulmonary arterial hypertension (PAH) rats. A: Hematoxylin and eosin (H E) staining of lung tissue from Sprague-Dawley rats with PAH shows pulmonary arteries (PAs) wall thickness ( arrows ). After SU5416 injection, rats were kept in hypoxia for 3 weeks and then maintained in normoxia for 5 weeks. B: α-Smooth muscle actin (SMA) antibody staining in the media of small PAs (brown; arrows ). C: Kv11.1 antibody staining in the media of small PAs (brown; arrows ). D: Quantification of Kv11.1 channel expression (in arbitrary units; au) in small PAs of healthy and PAH rat lungs. E: Negative control for C with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated ( red lines ). n = 11 (control); n = 18 (PAH). * P

    Journal: The American Journal of Pathology

    Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

    doi: 10.1016/j.ajpath.2019.09.010

    Figure Lengend Snippet: Kv11.1 channel expression increases in pulmonary arterial hypertension (PAH) rats. A: Hematoxylin and eosin (H E) staining of lung tissue from Sprague-Dawley rats with PAH shows pulmonary arteries (PAs) wall thickness ( arrows ). After SU5416 injection, rats were kept in hypoxia for 3 weeks and then maintained in normoxia for 5 weeks. B: α-Smooth muscle actin (SMA) antibody staining in the media of small PAs (brown; arrows ). C: Kv11.1 antibody staining in the media of small PAs (brown; arrows ). D: Quantification of Kv11.1 channel expression (in arbitrary units; au) in small PAs of healthy and PAH rat lungs. E: Negative control for C with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated ( red lines ). n = 11 (control); n = 18 (PAH). * P

    Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H & E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

    Techniques: Expressing, Staining, Injection, Negative Control

    Kv11.1 channel expression gradually increases with the development of pulmonary arterial hypertension (PAH) in rats. A: Time course examination of Kv11.1 expression in PAH rats (brown; arrows ). For this experiment Fischer rats were injected with SU5416, placed in hypoxia for 3 weeks, and then maintained in normoxia for 2 weeks to obtain time points of 0, 1, 2, 3, 4, and 5 weeks after the SU5416 injection. B: Negative control for the corresponding images in A with the primary antibody omitted and only the secondary antibody used. C: Quantification of the changes in Kv11.1 channel expression [in arbitrary units (au)] with PAH development in small pulmonary arteries (PAs). The mean of the data is indicated ( red lines ). n = 10. * P

    Journal: The American Journal of Pathology

    Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

    doi: 10.1016/j.ajpath.2019.09.010

    Figure Lengend Snippet: Kv11.1 channel expression gradually increases with the development of pulmonary arterial hypertension (PAH) in rats. A: Time course examination of Kv11.1 expression in PAH rats (brown; arrows ). For this experiment Fischer rats were injected with SU5416, placed in hypoxia for 3 weeks, and then maintained in normoxia for 2 weeks to obtain time points of 0, 1, 2, 3, 4, and 5 weeks after the SU5416 injection. B: Negative control for the corresponding images in A with the primary antibody omitted and only the secondary antibody used. C: Quantification of the changes in Kv11.1 channel expression [in arbitrary units (au)] with PAH development in small pulmonary arteries (PAs). The mean of the data is indicated ( red lines ). n = 10. * P

    Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H & E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

    Techniques: Expressing, Injection, Negative Control

    Kv11.1 channel expression is increased in chronic obstructive pulmonary disease (COPD)-affected human lungs. A and B: Hematoxylin and eosin (H E) staining of the lung tissue in individuals of the indicated age and sex showing alveoli emphysema (a), bronchiole (b), peribronchial fibrosis ( asterisk ), perivascular fibrosis, and pulmonary artery (PA) wall thickness ( arrows ). C – H: Kv11.1 antibody staining of media of large PAs (diameter > 100 μm; black asterisks ) and small PAs (diameter

    Journal: The American Journal of Pathology

    Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

    doi: 10.1016/j.ajpath.2019.09.010

    Figure Lengend Snippet: Kv11.1 channel expression is increased in chronic obstructive pulmonary disease (COPD)-affected human lungs. A and B: Hematoxylin and eosin (H E) staining of the lung tissue in individuals of the indicated age and sex showing alveoli emphysema (a), bronchiole (b), peribronchial fibrosis ( asterisk ), perivascular fibrosis, and pulmonary artery (PA) wall thickness ( arrows ). C – H: Kv11.1 antibody staining of media of large PAs (diameter > 100 μm; black asterisks ) and small PAs (diameter

    Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H & E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

    Techniques: Expressing, Staining

    Kv11.1 channels are expressed in healthy rat lungs. A: Hematoxylin and eosin (H E) staining of Sprague-Dawley rat lung tissue showing a normal structure of a bronchiole (b), alveoli (a), thin interstitial alveolar wall, and normal pulmonary arteries wall thickness (pv; arrows ) in control rats. B: α-Smooth muscle actin antibody staining in the smooth muscle cell layer of a bronchiole ( asterisk ) and in the media of pulmonary arteries (PAs) at diameter > 100 μm ( black arrow ). Absence of α-smooth muscle actin antibody staining in the media of PAs at diameter

    Journal: The American Journal of Pathology

    Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

    doi: 10.1016/j.ajpath.2019.09.010

    Figure Lengend Snippet: Kv11.1 channels are expressed in healthy rat lungs. A: Hematoxylin and eosin (H E) staining of Sprague-Dawley rat lung tissue showing a normal structure of a bronchiole (b), alveoli (a), thin interstitial alveolar wall, and normal pulmonary arteries wall thickness (pv; arrows ) in control rats. B: α-Smooth muscle actin antibody staining in the smooth muscle cell layer of a bronchiole ( asterisk ) and in the media of pulmonary arteries (PAs) at diameter > 100 μm ( black arrow ). Absence of α-smooth muscle actin antibody staining in the media of PAs at diameter

    Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H & E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

    Techniques: Staining

    Kv11.1 channels are expressed in human lungs. Normal human lung hematoxylin and eosin (H E) staining in a 41-year-old man ( A ) and 65-year-old woman ( B ). Shown are sections of the lung composed of terminal bronchiole (b) and thin-walled alveoli (a). Also shown is a thin layer of alveoli connective tissue and a multitude of pulmonary vessels (pv; arrows ). C and D: Kv11.1 antibody staining of normal human lung in the 41-year-old man ( C , right upper lobe ) and 65-year-old woman ( D , left lower lobe), with the structural elements denoted in the same manner as in A and B . E and F: Kv11.1 staining in bronchial smooth muscle layer ( red arrows ) and in the media of pulmonary arteries (PAs) of diameter > 100 μm ( black arrows ) in the 41-year-old man ( E ) and 65-year-old woman ( F ). G and H: Arrows indicate the absence of Kv11.1 staining in small PAs (diameter

    Journal: The American Journal of Pathology

    Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

    doi: 10.1016/j.ajpath.2019.09.010

    Figure Lengend Snippet: Kv11.1 channels are expressed in human lungs. Normal human lung hematoxylin and eosin (H E) staining in a 41-year-old man ( A ) and 65-year-old woman ( B ). Shown are sections of the lung composed of terminal bronchiole (b) and thin-walled alveoli (a). Also shown is a thin layer of alveoli connective tissue and a multitude of pulmonary vessels (pv; arrows ). C and D: Kv11.1 antibody staining of normal human lung in the 41-year-old man ( C , right upper lobe ) and 65-year-old woman ( D , left lower lobe), with the structural elements denoted in the same manner as in A and B . E and F: Kv11.1 staining in bronchial smooth muscle layer ( red arrows ) and in the media of pulmonary arteries (PAs) of diameter > 100 μm ( black arrows ) in the 41-year-old man ( E ) and 65-year-old woman ( F ). G and H: Arrows indicate the absence of Kv11.1 staining in small PAs (diameter

    Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H & E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

    Techniques: Staining